OncoMatch/Clinical Trials/NCT05789303
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Is NCT05789303 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Belantamab mafodotin and Carfilzomib for multiple myeloma.
Treatment: Belantamab mafodotin · Carfilzomib · Pomalidomide · Dexamethasone — Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy. Participation in this research will last about 6 -24 months, but it may be less or more depending on your response to treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-myeloma therapy
Subjects with relapsed or refractory multiple myeloma requiring systemic therapy, who have progressed after 2+ prior lines of anti-myeloma treatments.
Cannot have received: belantamab mafodotin (belantamab mafodotin)
Exception: prior refractory status only
Prior refractory status to belantamab mafodotin
Cannot have received: investigational drug or approved systemic anti-myeloma therapy (including systemic steroids)
Subject must not have used an investigational drug or approved systemic anti-myeloma therapy (including systemic steroids) within 14 days preceding the first dose of study drug.
Cannot have received: radiotherapy
Exception: localized radiotherapy to a single site 1 week before start is permissible
Radiotherapy to multiple sites within 3 weeks before start of protocol treatment (localized radiotherapy to a single site 1 week before start is permissible).
Cannot have received: major surgery
Subject must not have had major surgery ≤ 2 weeks prior to initiating study treatment.
Lab requirements
Blood counts
adequate organ function, defined by clinically confirmed lab values set by the study team
Kidney function
adequate organ function, defined by clinically confirmed lab values set by the study team
Liver function
adequate organ function, defined by clinically confirmed lab values set by the study team
Subject must have adequate organ function, defined by clinically confirmed lab values set by the study team.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Chicago Medicine Comprehensive Cancer Center · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify